TranS1 News Releases

Stay up-to-date with the latest announcements from TranS1 about our minimally invasive spine products, upcoming events, and more.

February 21st, 2017

TranS1 launches Capital Bone Graft Harvester

New technology provides surgeons with MIS solution for autologous bone capture

DENVER — Feb. 21, 2017 — TranS1®, a medical device company focused on breakthrough spine solutions that minimize tissue trauma, today announced the release of the Capital Bone Graft Harvester, a new technology that allows for fast, reliable, and reproducible harvesting of autograft material from the iliac crest.

“Cancellous bone from the iliac crest is the gold standard for fusion1,” said Jeff Schell, President and CEO of TranS1. “The innovative design of the Capital Bone Graft Harvester is intended to solve the deficiencies with traditional iliac crest harvesting approaches and provide surgeons a reproducible MIS autograft solution for use in spine procedures.” 

Unlike the traditional open approach, the Capital Bone Graft Harvester allows access to the iliac crest with a one centimeter tissue access dilator.  All grafting is performed through that opening. The unique construction of the instrumentation creates access for the capture of bone by utilizing ridges within the tube internal diameter. Shaft fenestration facilitates bone drilling and capture while providing ease of autograft ejection. The device also extracts the graft dowel while shielding surrounding tissue. 

The iliac crest is targeted using a true anterior posterior fluoroscopic image. Based on surgeon preference, the iliac crest may be accessed from a lateral or prone patient position. The result, unlike other bone graft substitutes, is a natural sample of the patients’ own bone that can be used in a fusion surgery and contains osteoinductive, osteoconductive, and osteogenic properties2.

The Capital Bone Graft Harvester is one of several technologies TranS1 has released over the past six months. The company offers a full suite of MIS solutions for spine to compliment its flagship, the AxiaLIF+® System for pre-sacral interbody fusion. The Capital Bone Graft Harvester is patent pending and is currently available on the market. 


About TranS1®

TranS1® develops medical breakthroughs to solve spinal pathologies that minimize trauma to the tissues surrounding the spine. The company’s flagship product, AxiaLIF+®, is a minimally invasive option for surgeons to accomplish spinal fusion at the L5-S1 joint. The Colorado-based company was named Denver’s Most Innovative Workplace by the 80/95 Awards, presented by the Denver Post.  For more information, please visit



1  Le Pape, Du Pouget, Cloche, Campana, Obeid, Boissiere, Vital. (2016) “Anatomic feasibility of a new endopelvic approach for iliac crest bone harvesting.” Surgical and Radiologic Anatomy. Dec;38(10):1191-1194.

2 Prasanna Kumar, Belliappa Vinitha, and Ghousia Fathima. (2013) “Bone Grafts in Dentistry.” Jun; 5(Suppl 1): S125–S127.doi:  10.4103/0975-7406.113312


November 29th, 2016

TranS1 recognized as a leading innovator in Colorado

Denver-based medical device company received accolades from three top business organizations for its 2016 accomplishments

DENVER – November 29th, 2016 – TranS1® today announced that it earned recognition for its efforts in innovation, leadership, and the advancement of new technologies in Colorado from three leading business organizations.

  • Winner, Most Innovative Workplace in Denver – TranS1® was recognized at the 80/95 Awards, sponsored by the Denver Post, as the most innovative workplace in Denver.  The 80/95 Awards were presented during Millennial Weekend Denver and showcase companies that have millennial leaders who make an impact on culture, enterprise, and society.
  • Honoree, Top 250 Private Companies in Colorado – TranS1® was named one of the Top 250 Private Companies in Colorado by ColoradoBiz Magazine.  The awards recognize the top 250 private companies in the state by revenue.

“TranS1’s® mission is to develop breakthrough medical innovations, therefore, it is an honor to be recognized by 80/95, Colorado Technology Association, and ColoradoBiz Magazine as a leading innovator in Colorado,” said Jeff Schell, president and CEO of TranS1®. “The strong talent base and business community in Denver are crucial factors in our success.”

TranS1® established operations in Denver in February 2015.  The company offers technologies that solve spinal pathologies, including the AxiaLIF+ system, which has been on the market for a decade.  TranS1®released a suite of new products in October 2016.  Among those products are an MIS Pedicle Screw System, a TLIF/PLIF IBF System, and a Cervical Interbody System.  Also in October, the company announced plans to launch the Capital Bone Graft Harvester and Pylon Graft Deliverysystem in 2017.

“I am proud of our team’s accomplishments in 2016, and with more than 10 new technologies in our pipeline, including multiple proprietary innovations poised to launch, 2017 will prove to be an even bigger year,” Schell explained.

About TranS1®

TranS1® develops medical breakthroughs to solve spinal pathologies that minimize trauma to the tissues surrounding the spine. The company’s flagship product, AxiaLIF+®, is a minimally invasive option for surgeons to accomplish spinal fusion at the L5-S1 joint. For more information, please visit


April 6th, 2016

TranS1 Names Brandon Arthurs, Vice President of Research & Development

“Brandon Arthurs, a certified professional engineer, will lead collaborations with surgeons and entrepreneurs to bring medical innovations to market. Arthurs brings nearly two decades of successful technical leadership and product development, as well as an extensive track record of securing medical patents.”

February 02, 2016

TranS1 Names Chris Groppa Chief Marketing Officer and Director of Reimbursement

“In this role, Groppa will oversee the development and implementation of all marketing activities and will continue to oversee TranS1’s insurance reimbursement strategy. He brings more than a decade of digital marketing, communications and product development expertise to the TranS1 team.”

November 10, 2015

Economic Analysis Demonstrates Substantial Spine Surgery Cost Savings with TranS1's AxiaLIF+

“The AxiaLIF procedure from TranS1®, a medical device company focused on designing, developing and marketing products to treat degenerative conditions of the spine, provides an estimated savings of $3,500 when compared to the Transformational Lumbar Interbody Fusion (TLIF) surgery option according to a recent study.”

September 21, 2015

TranS1 Announces John Miller as New Vice President of Sales

“Healthcare industry veteran John Miller will lead sales efforts for innovative medical device company’s AxiaLIF® product as well as future offerings”